Efficacious formulation of anti-malarial dry suspension for pediatric use

S. Mohammad¹, S. N. H. Shah¹, B. Nasir¹, Q. Khan², A. Aslam³, R. Riaz³, M. Sher⁴, S. Karim⁵ and G. Murtaza⁶*

¹Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
²Department of Health, Government of Punjab, Layyah, Pakistan.
³Multan College of Pharmacy and Management Sciences, Multan, Pakistan.
⁴Department of Chemistry, University of Sargodha, Sargodha, Pakistan.
⁵Department of Pharmacy, University of the Punjab, Lahore, Pakistan.
⁶Department of Pharmaceutical Sciences, COMSATS Institute of Information Technology, Abbottabad-22060, Pakistan.

This study was designed for concealing the bitter taste of an anti-malarial drug, artemether, by using various coating substances. Four granular formulations (formulations A, B, C and D) of artemether were prepared using different excipients and then were coated using methocil™ E5 and opadry® enteric solutions in a simple coating pan. In the initial 2 min, the cumulative percentage amount of drug release in phosphate buffer at pH 6.8 from pure artemether and formulation A, B, C and D was 59.4 ± 4.2, 55.7 ± 3.5, 48.2 ± 3.8, 43.4 ± 4.1 and 30.8 ± 3.7, respectively. Formulation D exhibited minimum bitterness as its taste masking efficacy (44.73 ± 4.98) was significantly (P < 0.05) greater than other formulations. It can be concluded from results that granules of formulation D prepared by sodium metabisulphite and methyl paraben sodium and coated by opadry® enteric had maximally reduced the bitterness of artemether with suitable dissolution behavior.

Key words: Artemether, dry suspension, in vitro test, taste analysis.

INTRODUCTION

Artemether is a derivative of artemisinin, which has exhibited greater hydrophilicity compared to that of artemisinin and possesses an efficient activity as a first-line anti-malarial drug with little toxicity (Chen et al., 2004). The customary Chinese herb Artemisia annua is a source of this drug (Dhingra et al., 2000). Being a drug with very bitter taste, it is needed to prepare an oral dosage form which can mask the unpleasant taste of artemether. Its adult dose is 1.6 mg/kg of body weight per dose given every 8 hourly. Otherwise, the identical total dose may be administered once daily for three days (Ashley et al., 2005). They are widely available in the different pharmaceutical dosage forms including tablets, injections, suppositories and dry powders (Van der Meersch, 2005).

The oral route of drug delivery is not suitable especially in children who are not likely to accept the bitter or unpleasant tastes of medicines (Roy, 1994; Szejtli and Szente, 2005). There is a long list of oral drugs like artemether and sparfloxacin that have bitter taste (Shirai et al., 1993, 1994; Katsuragi et al., 1995, 1997; Yajima et al., 1999), which is responsible for non-compliance of the patients. Therefore, many physical methodologies like encapsulation and techniques for chemical modification have been introduced to mask the unpleasant and bitter taste of medicines.
Table 1. Formulation and process variables used in the preparation of artemether granules.

| Parameter              | Group 1                         | Group 2                         |
|------------------------|---------------------------------|---------------------------------|
|                        | Formulation A                   | Formulation B | Formulation C | Formulation D |
| Artemether (mg)        | 35                              | 35                        | 35            | 35            |
| Starch (g)             | 3.5                             | 3.5                       | -             | -             |
| PVP-K30 (g)            | 4.5                             | 4.5                      | -             | -             |
| IPA (ml)               | 10                              | 10                       | -             | -             |
| Carbopol 934P (g)      | -                               | -                         | 25            | 25            |
| Sodium metabisulphite (g) | -                             | -                        | 60            | 60            |
| Methyl paraben sodium (g) | -                             | -                         | 80            | 80            |
| Distilled water (ml)   | Qs (~10)                        | Qs (~10)                  | Qs (~15)      | Qs (~15)      |
| Coating solution       | Methocil™ E5                    | Opadry® enteric           | Methocil™ E5  | Opadry® enteric |
| Drying time (min)      | 45                              | 45                        | 50            | 50            |

MATERIALS AND METHODS

Artemether was obtained as a gift sample from AMSON Vaccines & Pharma (Pvt.) Ltd. Islamabad, Pakistan. Methocel® E5 was procured from Dow Chemical Co., Midland. Opadry® was bought from Colorcon, West Point, PA. Carbopol 934P was purchased from B.F. Goodrich, Cleveland, OH, USA. Polyvinylpyrrolidone (PVP-K30) and isopropyl alcohol (IPA) were procured from Fluka (Buchs, Switzerland). All these chemicals and reagents were of analytical grade and were used without any alteration.

Preparation of artemether granules

For solubility study, a surplus quantity of pure artemether was added to water for the preparation of test samples, shaken at 100 rpm and 37°C for 120 h using an orbital shaker (Eras, Pakistan) and then centrifuged for 10 min. The drug samples were withdrawn using a syringe attached with a 0.40 μM syringe filter, diluted and instantly analyzed using validated high performance liquid chromatography (HPLC) method (Gradient SPD 10A, Shimadzu, Japan; method validation results are not presented) at 209 nm for drug analysis (Sharma et al., 2012). This experiment was repeated in triplicate.

For granulation, low-shear mixer (laboratory-scale, Asraw, Pakistan) was employed to fabricate the wet granules of artemether (formulations A, B, C and D in Table 1). Each batch size consisted of 50 g. During the preparation, powders were mixed using impeller rotated at 100 rpm for 10 min. For wetting the whole mixture, granulation liquid was mixed using impeller rotated at 400 rpm for 10 min. The formulated granules were dried at 60°C (at reduced pressure) with periodic shaking using impeller at a speed of 100 rpm for 10 s after every 100 s and angling the bowl to enhance the exposed surface area of granules for the maximum evaporation of solvents (Sharma et al., 2012). After allowing the granules to cool down at room temperature as thin layers in a tray, sieving was done to fractionate on the basis of granule size. In order to coat the formulated granules (Table 1), two coating solutions namely Methocel™ E5 (prepared by thorough mixing the solution of methocel™ E5 in 250 g of IPA with the solution of titanium dioxide and talcum in 50 ml of methylene chloride) and opadry® enteric (prepared by mixing opadry® enteric in methylene chloride and IPA) (Sharma et al., 2012) were employed using conventional coating pans.

Characterization of granules

Size measurement

Sieve analysis technique using vibrating shaker (Octagon Digital, Endecotts, London, UK) was employed to determine the granule size distribution at medium vibration level for 15 min and three standard sieves (Scientific Instruments, Milan, Italy) in the range 250 - 2000 μM. The collected fractions of granules were stored in desiccators at 30 ± 2°C (Sharma et al., 2012). This experiment was repeated in triplicate.

Artemether content determination

Granules (50 mg) were dissolved in phosphate buffer pH 6.8 (100 ml) and the contents of artemether in each formulation were determined using HPLC (Sharma et al., 2012). This experiment was repeated in triplicate.
Loss-on-drying (LOD)

The LOD Box was placed at 105°C in oven for 30 min, cooled in desiccator and then weighed the empty LOD Box (W1) using analytical balance. One gram of sample was taken in LOD Box and weighed (W2). The LOD Box then put in the oven at 60°C for 1 h, cooled in desiccators and weighed (W3). The percentage was found out according to following formula:

\[
LOD \, (\%) = \frac{W_2 - W_3}{W_2 - W_1} \times 100
\]

In vitro dissolution tests

In vitro dissolution tests for artemether release were carried out in the following conditions: USP 24 paddle method (Pharmatest, Steinhein, Germany), paddle speed 60 rpm, phosphate buffer pH 6.8 (900 ml), temperature of medium 37 ± 1°C. 35 mg of artemether in each sample, samples collection at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 10 h, sample analysis via HPLC Gradient SPD 10A (Shmadzu, Japan) at 209 nm, and experimentation in triplicate.

Pleasant taste perception test

Rather than the solid samples, pleasant taste perception (PTP) test was carried on the solution of granules for the evaluation to minimize the extensive changeability of drug concentration in the mouth due to various salivation states among volunteers. At the Gustatory Evaluation Laboratory of the Institute of Biotechnology, Bahauddin Zakariya University, Multan-Pakistan, PTP test was carried out by six young human volunteers as presented previously (Robson et al., 1999). To determine the perception and bitterness recognition threshold, seven standard solutions of pure artemether in distilled water at different concentration levels (0.00, 0.01, 0.025, 0.05, 0.1, 0.2% and 0.4% (w/v)) were prepared. The volunteers were then asked to taste 0.1% solution (5 ml) by retaining it in mouth for 5 seconds followed by requesting them to tick any of the following option: (i) “I feel a bitter taste”, (ii) “I do not feel any difference between 0.00% and 0.05% solutions”, and (iii) “I feel something but I cannot identify the taste”. For the volunteers who replied “I do not feel any difference between 0.00% and 0.05% solutions”, they were asked for tasting 0.1% solution, while the volunteers who replied “I feel a bitter taste”, they were asked to taste 0.025% solution. As a result, the perception threshold at a level of 0.05% (w/v) with a range of 0.025 - 0.08% (w/v), as well as bitterness recognition threshold at a level of 0.08% (w/v) with a range of 0.06 - 0.2% (w/v) was set. An expert team evaluated some solutions for taste using various concentration levels of artemether to achieve homogeneous sensation of bitterness intensity among the human volunteers. Then the volunteers were communicated the bitterness scores in arrange of 0-100 for these solutions.

Formulation of dry suspension

Keeping in view the behavior of finished coated granules and the raw materials, the finished dry suspension (each pack of 25 g powder) was formulated as follows:

Strength of the Suspension: 160 mg artemether / 80 ml
Targeted pH of Diluted Product: 3 - 5
Assay on granules on anhydrous basis: 40%

All the ingredients (Table 2) were mixed well in a small mixing bag for 15 min. This powder was then carefully shifted to small graduated cylinder. Then deionized water was added till the final volume of the suspension becomes 80 ml. The volume of water used was noted. The suspension was then shifted to a polyvinyl chloride (PVC) bottle and capped, then shaken very well and the final volume of the suspension was noted in the bottle by putting a mark (same volume of the water was added to the granules to bring the suspension on the required concentration). Initially the taste of diluted suspension was checked and it was observed that the taste was very good, and the pH was 3.9. Subsequently, it was then stored in the refrigerator and checked after seven days. All the physical parameters were satisfactory.

Statistical analysis

The significance of difference among parameters of various granular formulations was analyzed using the unpaired student’s t-test and a value of P < 0.05 was considered significantly different.

### Table 2. Excipients used to formulate finished dry suspension.

| No. | Ingredients                          | Quantity (g)  |
|-----|-------------------------------------|---------------|
| 1   | Artemether coated granules          | 0.40          |
| 2   | Sugar fine                          | 23.445        |
| 3   | Aerosil                             | 0.090         |
| 4   | Xanthan gum                         | 0.180         |
| 5   | Tit. Dioxide                        | 0.050         |
| 6   | Orange flavor                       | 0.050         |
| 7   | NaCl                                 | 0.225         |
| 8   | Citric acid                         | 0.56 (q.s. to adjust pH at 3-5) |
|     | Total weight                        | 25 g / Pack   |
RESULTS AND DISCUSSION

The solubility of artemether in water was low (0.14 ± 0.02 mg/ml), which is in accordance with that of previous reports (Sharma et al., 2012; Chukwu et al., 1991; Al-Omranm et al., 2002; Hashimoto et al., 2002). The contents of artemether in the groups 1 and 2 formulations were non-significantly (p > 0.05) different from each other (they were in the range of 89.2 ± 0.1 - 92.1 ± 0.2% (w/w)). Moreover, all the formulations were developed for producing good quality and uniform shape granules. The granules of formulation A exhibited smaller size principally, which could be attributed to the incorporation of PVP (Al-Omranm et al., 2002). However, the granules of formulation B were comparatively larger in size than those of formulation A. The cumulative frequency for group 1 formulations was >37, 30 and 18% for granules with a size range of <250, 250-500 and >1500 µM, respectively. The cumulative frequency for group 2 formulations was 20, 44 and 36% for granules with a size range of <250, 250-500 and >1500 µM, respectively. On the whole, group 2 formulations produced significantly (p < 0.05) larger granules as compared to that of group 1 formulations. The percentage yield of granules from group 1 formulations (96.6 ± 0.2%, w/w) was non-significantly (p > 0.05) greater than that of group 2 formulations (97.1 ± 0.5%, w/w), indicating little loss of materials through the process of granulation.

Figure 1 depicts the in vitro dissolution behavior of the developed granules in comparison of pure artemether. In the initial 2 min, the cumulative percentage amount of drug released from pure artemether and formulation A, B, C and D was: 59.4 ± 4.2, 55.7 ± 3.5, 48.2 ± 3.8, 43.4 ± 4.1, and 30.8 ± 3.7, respectively. These results were in accordance with the previous results (Sharma et al., 2012). Furthermore, the results observed from the PTP test represented that the taste-masking approach depends upon the technique of granulation as well as the selection of formulation and coating substances. The bitter taste intensity scores for formulation A, B, C, and D were 83.31 ± 3.26 (p > 0.05), 76.27 ± 5.21 (p > 0.05), 70.47 ± 4.45 (p > 0.05), and 44.73 ± 4.98 (p > 0.05), correspondingly as compared to that of pure drug. The PTP results verified the excellent taste masking efficiency of formulation D granules as compared to other formulations. These results are in accordance with the previous results (Sharma et al., 2012; Ameye et al., 2002; Ansari et al., 2009; Beatrice et al., 2004). LOD of granules were determined 3.76 ± 0.21, 3.45 ± 0.11, 3.25 ± 0.02 and 4.01 ± 0.01, respectively and results were in the standard range (4.0%).

After getting reproducible results from the coated granules of DHA, formulation of finished dry suspension was carried out. Dry suspension is usually a stable dosage form but very technical, since any wrong choice of the excipients may lead to a number of problems in the product development when reconstituted with water for use. After seven days (the maximum time that the patient can store the suspension in refrigerator. The product was discarded after seven days), the assay of the dry suspension was done [107.63 ± 4.25 (LOD was 3.5)] and pH was 4.25 (limit 3 - 5) and all physical parameters like color (off white suspension), texture (thick suspension), taste (pleasant) and smell (fresh orange smell) were determined.

In an earlier work, a pediatric dry suspension had been developed with Artemether as active compound with concentration of 180 mg/60 ml after reconstitution in water (Gabriels, 2004), whereas in our formulated dry suspension (Table 2) artemether as active compound having 160 mg/80 ml is comparable with similar characteristics that offers several advantages: (i) maintenance of the chemical stability of the drug until (and after) reconstitution, (ii) reduction in transportation cost and possibility to adapt the dosage for different age groups. Once the particles of dry suspension have been wetted, they must be distributed uniformly throughout the liquid medium (Atemnkeng, 2007). The preparation contains macromolecules as suspending agents with thixotropic behavior. Other solid excipients include taste and coloring agents (sugar fine, orange flavor and titanium dioxide). In addition, a fair amount of aerosil was added to protect the active ingredient against moisture (LOD was 3 - 4%). Hence, this makes the preparation to contain a high amount of solid excipient powder making the analysis of the active ingredient and preservatives complex. The advantages of high-precision dosing,
manufacturing efficiency and patient compliance make solid dosage form like dry suspension, the most popular (Patel, 2006).

Conclusion

Thus far, the trials for the formulation of granules using different agents, as well as the trials for coating of these granules using different coating materials have been explored. The dry suspension was formulated and then evaluated by physical and chemical means. The concentration of the suspending agents, xanthan gum, was optimized to obtain a permanently physical stability of the suspension after reconstitution. This characteristic was required due to the low dosage of the drug in the suspension, namely 2 mg/ml. Viscosity was taken as 115 mPa·s. The trials for the formulation of granules using different coating materials have been explored. The results showed that granules of the active compounds in the range of 1 to 5 mg/ml, in which the aesthetic aspect of the suspension was optimized. This study has, therefore, opened a new approach for masking the taste of bitter drugs.

REFERENCES

Al-Omran MF, Al-Suwayeh SA, El-Helw AM, Saleh SI (2002). Taste masking of diclofenac sodium using microencapsulation. J. Microencapsul. 19:45-52.

Ameye D, Keleb E, Vervaet C, Remon JP, Adams E, Massarat DL (2002). Scaling-up of a lactose wet granulation process in Mi-Pro High shear mixers. Eur. J. Pharm. Sci. 17:247-251.

Ansari MT, Iqbal I, Sunderland VB (2009). Dihydroartemisinin- cyclodextrin Complexation: Solubility and Stability. Arch. Pharm. Res. 32:155-165.

Ashley E A, McGreedy R, Hutagulang R, Phaiphun L, Sllht T, Proux S, Thwai K L, Barends M (2005). "A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperazine for the treatment of uncomplicated, multidrug-resistant falciparum malaria". Clin. Infect. Dis. 41:425-432.

Barra J, Lesure F, Doekler E (1999). Taste masking as a consequence of the organisation/organization of powder mixes. Pharm. Acta Helv. 74:37-42.

Beatrice A, Cristina C, Nadia P, Dario V, González-Rodríguez ML, Lorenzo M, Lorenzo R (2004). Characterization and taste-masking evaluation of acetaminophen granules: comparison between different preparation methods in a high-shear mixer. Eur. J. Pharm. Sci. 21:295-303.

Chen H, Zhou H, Wang W, Wu G (2004). Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother. Pharmacol. 53:423-432.

Chukwu A, Agarwal SP, Adikwu MU (1991). Some properties of chloroquine phosphate and quinine hydrochloride microcapsules. STP Pharm. Sci. 1:117-120.

Cuña M, Lorenzo-Lamosa LM, Vila-Jato JL, Torres D, Alos MJ (1997). pH dependent cellulosic microspheres containing cefuroxime axetil: stability and in vitro release behaviour. Drug Dev. Ind. Pharm. 23:259-265.

Dhingra V, Vishweshwar RK, Lakshmi NM (2000). Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. 66:279-300.

Hakim MS (2011). Pharma guide, Medico Publishers, Karachi, Pakistan.

Hashimoto Y, Tanaka M, Kishimoto H, Shizowa H, Hasegawa K, Matsuyama K, Uchida T (2002). Preparation, characterization and taste-masking properties of polyvinylacetate microspheres containing trimebutine. J. Pharm. Pharmacol. 54:1323-1328.

Katsuragi Y, Mitsui Y, Umeda T, Otsuji K, Yamashawa S, Kurihara K (1997). Basic studies for the practical use of bitterness inhibitors: selective inhibition of bitterness by phospholipids. Pharm. Res. 14:720-724.

Katsuragi Y, Sugiuara Y, Lee C, Otsuji K, Kurihara K (1995). Selective inhibition of bitter taste of various drugs by lipoprotein. Pharm. Res. 12:658-662.

Robson HJ, Craig DQM, Deutsch D (1999). An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres. Part I. The influence of the dissolution medium on the drug release profile and the physical integrity of the microspheres. Int. J. Pharm. 190:183-192.

Roym GM (1994). Taste masking in oral pharmaceuticals. Pharm. Technol. Eur. 94:24-35.

Sharma D, Chopra R, Bedi N (2012). Development and evaluation of paracetamol taste masked orally disintegrating tablets using polymer coating technique. Int. J. Pharm. Pharmacol. Sci. 4:129-134.

Shimano K, Konno O, Miwa A, Higashi Y, Goto S (1995). Evaluation of uniform-sized microcapsules using a vibration-nozzle method. Drug Dev. Ind. Pharm. 21:3311-347.

Shirai Y, Sogo K, Fujioka H, Nakamura Y (1994). Role of low-substituted hydroxypropylcellulose in dissolution and bioavailability of novel fine granule system for masking bitter taste. Biol. Pharm. Bull. 17:427-431.

Shirai Y, Sogo K, Yamamoto K, Kojima K, Fujioka H, Makita H, Nakamura Y (1993). A novel fine granule system for masking bitter taste. Biol. Pharm. Bull. 16:172-177.

Szetl J, Szente L (2005). Elimination of bitter, disgusting tastes of drugs and foods by Cyclodextins. Eur. J. Pharm. BioPharm. 61:115-125.

Wilson ML, Ritshel WA, Sakr A (1994). Development of an ibuprofen lozenge for the elderly. Pharm. Ind. 56:836-841.

Yajima T, Umeji N, Itai, S (1999). Optimum spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. Chem. Pharm. Bull. 47:220-225.

Mohammad et al. 2633